In a filing, UroGen Pharma Ltd revealed its Chief Medical Officer Schoenberg Mark unloaded Company’s shares for reported $50698.0 on Jan 31 ’25. In the deal valued at $11.14 per share,4,551 shares were sold. As a result of this transaction, Schoenberg Mark now holds 145,666 shares worth roughly $1.41 million.
Then, Smith Jason Drew sold 7,379 shares, generating $82,202 in total proceeds. Upon selling the shares at $11.14, the General Counsel now owns 26,468 shares.
Before that, Schoenberg Mark sold 859 shares. UroGen Pharma Ltd shares valued at $11,236 were divested by the Chief Medical Officer at a price of $13.08 per share. As a result of the transaction, Schoenberg Mark now holds 145,091 shares, worth roughly $1.41 million.
Scotiabank initiated its UroGen Pharma Ltd [URGN] rating to a Sector outperform in a research note published on April 16, 2025; the price target was $23. Guggenheim began covering URGN with “Buy” recommendation on August 22, 2024. Jefferies revised its rating on February 08, 2023. It rated URGN as “a Hold” which previously was an “a Buy”.
Price Performance Review of URGN
On Tuesday, UroGen Pharma Ltd [NASDAQ:URGN] saw its stock fall -11.51% to $9.69. Over the last five days, the stock has lost -9.94%. UroGen Pharma Ltd shares have fallen nearly -9.01% since the year began. Nevertheless, the stocks have fallen -32.05% over the past one year. While a 52-week high of $20.70 was reached on 03/24/25, a 52-week low of $8.94 was recorded on 04/10/25. SMA at 50 days reached $10.56, while 200 days put it at $12.01.
Levels Of Support And Resistance For URGN Stock
The 24-hour chart illustrates a support level at 9.08, which if violated will result in even more drops to 8.47. On the upside, there is a resistance level at 10.85. A further resistance level may holdings at 12.01. The Relative Strength Index (RSI) on the 14-day chart is 42.52, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.20, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 87.11%. Stochastics %K at 52.99% indicates the stock is a holding.
The most recent change occurred on April 27, 2022 when Berenberg began covering the stock and recommended ‘”a Buy”‘ rating along with a $20 price target.
